RxDoctor Payments Data

Daniela Jipa, MD

Internal Medicine · Columbus, OHNPI 1396782181

Payments from drug & device makers

$776in general payments, 2019–2025

Across 38 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$163
  • Novo Nordisk$121
  • AstraZeneca$107
  • Amarin Pharma, Inc.$90
  • Lilly USA, LLC$68
  • GSK$39
  • plus $188 from 9 others

What the payments were for

  • Food & beverage$776100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$776 in reported general payments places this provider in the 70th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$38,140
Medicare patients
125
Services billed
1,447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban63$78,822
TrulicityDulaglutide16$32,497
OzempicSemaglutide18$28,124
JanuviaSitagliptin Phosphate28$27,689
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$24,740
FarxigaDapagliflozin Propanediol15$24,099
MyrbetriqMirabegron11$13,600
Atorvastatin Calcium390$3,337
Venlafaxine Hcl ErVenlafaxine Hcl38$1,919
Rosuvastatin Calcium175$1,851
Metoprolol Succinate75$1,711
Levothyroxine Sodium225$1,544
Memantine Hcl36$1,302
Lisinopril256$1,266
Valsartan24$1,073

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$78,82263 claims
Lilly USA, LLCTrulicity$68$32,49716 claims
Novo NordiskOzempic$121$28,12418 claims
MerckJanuvia$23$27,68928 claims
GSKTrelegy Ellipta$39$24,74027 claims
AstraZenecaFarxiga$107$24,09915 claims
AbbVieSynthroid$12$93120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →